Simultaneous Kidney and Pancreatic Islet Transplant: A French First Offers Hope for Type 1 Diabetes and Renal Failure Patients

In a groundbreaking achievement, transplant teams at Toulouse University Hospital (CHU de Toulouse) in France have successfully performed the nation’s first simultaneous transplant of a kidney and pancreatic islets. This innovative procedure offers a modern treatment pathway for patients battling both type 1 diabetes and renal failure, potentially eliminating the require for dialysis and reducing insulin dependence.

Addressing Complex Medical Challenges

The patient, suffering from both type 1 diabetes and kidney failure, was not a candidate for a traditional combined kidney-pancreas transplant due to “major vascular constraints.” Instead, doctors opted for a dual approach: a kidney transplant to address renal failure and a transplant of pancreatic islets – the insulin-producing cells of the pancreas – to improve glycemic control.

The Maastricht 3 Donor and Islet Isolation

The organs and islets were sourced from a Maastricht 3 donor, meaning the donor died after cardiac arrest following a decision to cease medical treatment. CHU de Toulouse explains that organs and cells from these donors experience a period of reduced blood flow after death, presenting unique challenges for transplantation.

The pancreas was transported to Montpellier University Hospital, where specialized teams isolated and prepared the Langerhans islets for transplantation. These islets were then transferred to Toulouse for the procedure.

The Transplant Procedure and Early Results

The operation involved two teams working in tandem: one focused on the kidney transplant, and the other injecting the donor’s pancreatic islets into the patient’s liver. The transplantation of Langerhans islets aims to “sustainably improve the patient’s glycemic balance and protect the transplanted kidney by limiting the risk of recurrence of diabetes on the graft,” according to the hospital.

Early results are promising. The patient is no longer reliant on dialysis, and their body is now producing some of its own insulin, leading to reduced insulin injections and stabilized blood sugar levels.

Future Implications and Ongoing Research

Dr. Laure Esposito, the nephrologist who coordinated the operation, believes that pancreatic islet transplants hold significant promise for improving patient survival, protecting the transplanted kidney, and enhancing the quality of life for those with both type 1 diabetes and renal failure. “Allowing patients to no longer be dialyzed and no longer diabetic is truly a wonder and daily satisfaction,” she stated.

Research continues to explore ways to overcome the shortage of donor islets. Researchers are investigating methods to increase the number of patients treated with available donor islets and are also exploring the differentiation of human embryonic stem cells into beta cells as a potential solution.

Further studies, such as the 20-year single-center study in Italy evaluating long-term outcomes of islet transplantation alone, are crucial to optimizing immunosuppressive regimens and maximizing graft survival and insulin independence in type 1 diabetes patients.